COVID-19 Antivirals pregnancy registry

In collaboration with all UK Health Departments and the Medicines and Healthcare products Regulatory Agency (MHRA), UKTIS are monitoring the safety of new COVID-19 antivirals when taken in or around pregnancy.

Who can report to the registry?

  • Healthcare professionals
  • Pregnant women
  • Partners of pregnant women

If you live in the UK and (1) you have a patient that has used a COVID-19 antiviral medication when they were pregnant or shortly before pregnancy, or (2) if you used a COVID-19 antiviral medication when you were pregnant, or (3) if you used a COVID-19 antiviral medication around the time your partner conceived, please report the pregnancy to UKTIS today.

To report a pregnancy to UKTIS, please contact us by telephone (0344 892 0909, available 9am to 5pm, Monday to Friday excluding bank holidays).

How does the registry work?

  • Healthcare professionals and pregnant women/partners of pregnant women in England, Scotland and Wales can report pregnant women or the partners of pregnant women who used COVID-19 antivirals either during pregnancy or around the time of conception to UKTIS. This reporting does not require consent from the patient (England and Wales – Section 251 Exemption – PHE CAP approval number 13091, Scotland – approval pending). Reported pregnancies are subsequently followed-up using standardised procedures.
  • Healthcare professionals in Northern Ireland cannot currently report pregnant women to the registry. However, pregnant women and partners of pregnant women who have used COVID-19 antivirals during pregnancy or around the time of conception can self-report their pregnancy to UKTIS.

For more information about how the registry works, see here.

To report a pregnancy to UKTIS, please contact us by telephone (0344 892 0909, available 9am to 5pm, Monday to Friday excluding bank holidays).

Information about the safety of COVID-19 antivirals

If you are looking for information about the safety of COVID-19 antivirals, please see our information sources below:

Summary Information for Healthcare Professionals

Molnupiravir (manufacturer information: Lagevrio)

Paxlovid (nirmatrelvir/ritonavir – see COVID-19 antivirals section)

Summary Information for Patients

Molnupiravir (manufacturer information: Lagevrio)

Paxlovid (manufacturer information: Paxlovid)

Information about COVID-19 antiviral clinical trials

PANORAMIC trial